Renaissance Technologies’s GSK GSK Stock Holding History

Renaissance Technologies’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.2M	Sell	311,292 -724,280	-70%	-$39.2M	0.03%	718
2025 Q4	$50.8M	Sell	1,035,572 -952,381	-48%	-$44.4M	0.08%	291
2025 Q3	$85.8M	Sell	1,987,953 -262,900	-12%	-$10.3M	0.11%	198
2025 Q2	$86.4M	Buy	2,250,853 +268,700	+14%	+$10.3M	0.12%	188
2025 Q1	$76.8M	Sell	1,982,153 -773,040	-28%	-$28.3M	0.12%	209
2024 Q4	$93.2M	Buy	2,755,193 +419,700	+18%	+$15.1M	0.14%	163
2024 Q3	$95.5M	Sell	2,335,493 -12,500	-0.5%	-$511K	0.14%	150
2024 Q2	$90.4M	Buy	2,347,993 +554,600	+31%	+$23.3M	0.15%	141
2024 Q1	$76.9M	Sell	1,793,393 -971,800	-35%	-$40.1M	0.12%	198
2023 Q4	$102M	Sell	2,765,193 -146,800	-5%	-$5.27M	0.16%	137
2023 Q3	$106M	Sell	2,911,993 -110,141	-4%	-$3.91M	0.18%	116
2023 Q2	$108M	Sell	3,022,134 -1,207,317	-29%	-$43.3M	0.16%	137
2023 Q1	$150M	Sell	4,229,451 -2,107,700	-33%	-$73.7M	0.2%	99
2022 Q4	$223M	Sell	6,337,151 -3,016,906	-32%	-$100M	0.3%	57
2022 Q3	$275M	Buy	9,354,057 +1,370,600	+17%	+$51.9M	0.39%	39
2022 Q2	$434M	Sell	7,983,457 -26,080	-0.3%	-$1.44M	0.51%	27
2022 Q1	$436M	Sell	8,009,537 -170,800	-2%	-$9.28M	0.51%	27
2021 Q4	$451M	Buy	8,180,337 +648,800	+9%	+$33.7M	0.56%	27
2021 Q3	$360M	Buy	7,531,537 +282,480	+4%	+$14.2M	0.46%	34
2021 Q2	$361M	Buy	7,249,057 +238,640	+3%	+$11.5M	0.45%	34
2021 Q1	$313M	Sell	7,010,417 -4,406,720	-39%	-$200M	0.39%	41
2020 Q4	$525M	Sell	11,417,137 -3,246,586	-22%	-$149M	0.57%	25
2020 Q3	$690M	Sell	14,663,723 -1,777,280	-11%	-$89M	0.69%	17
2020 Q2	$838M	Sell	16,441,003 -2,020,160	-11%	-$104M	0.72%	19
2020 Q1	$874M	Buy	18,461,163 +3,239,084	+21%	+$173M	0.85%	14
2019 Q4	$894M	Buy	15,222,079 +1,180,720	+8%	+$65.7M	0.69%	15
2019 Q3	$749M	Buy	14,041,359 +1,831,934	+15%	+$94.2M	0.63%	15
2019 Q2	$611M	Buy	12,209,425 +791,345	+7%	+$39.7M	0.54%	19
2019 Q1	$596M	Buy	11,418,080 +2,104,160	+23%	+$105M	0.54%	15
2018 Q4	$445M	Buy	9,313,920 +1,205,760	+15%	+$59.4M	0.49%	22
2018 Q3	$407M	Buy	8,108,160 +644,640	+9%	+$32.8M	0.42%	28
2018 Q2	$376M	Buy	7,463,520 +973,280	+15%	+$49M	0.41%	27
2018 Q1	$317M	Sell	6,490,240 -1,244,400	-16%	-$58M	0.35%	36
2017 Q4	$343M	Buy	7,734,640 +184,480	+2%	+$8.52M	0.38%	34
2017 Q3	$383M	Buy	7,550,160 +79,760	+1%	+$4.05M	0.45%	22
2017 Q2	$403M	Buy	7,470,400 +3,948,720	+112%	+$211M	0.51%	18
2017 Q1	$186M	Buy	3,521,680 +1,053,280	+43%	+$53.4M	0.26%	61
2016 Q4	$119M	Buy	2,468,400 +1,724,400	+232%	+$85.2M	0.19%	89
2016 Q3	$40.1M	Buy	744,000 +335,360	+82%	+$18.4M	0.07%	362
2016 Q2	$22.1M	Buy	408,640 +24,160	+6%	+$1.27M	0.04%	613
2016 Q1	$19.5M	Buy	384,480 +243,360	+172%	+$12.1M	0.04%	670
2015 Q4	$7.12M	Sell	141,120 -1,003,360	-88%	-$51.1M	0.02%	1227
2015 Q3	$55M	Sell	1,144,480 -1,452,400	-56%	-$75.6M	0.13%	140
2015 Q2	$135M	Buy	2,596,880 +506,800	+24%	+$28.5M	0.31%	39
2015 Q1	$121M	Sell	2,090,080 -2,715,360	-57%	-$156M	0.26%	56
2014 Q4	$257M	Sell	4,805,440 -656,640	-12%	-$36.7M	0.62%	13
2014 Q3	$314M	Sell	5,462,080 -1,633,440	-23%	-$100M	0.86%	9
2014 Q2	$474M	Buy	7,095,520 +1,487,680	+27%	+$101M	1.11%	9
2014 Q1	$375M	Buy	5,607,840 +467,840	+9%	+$31.6M	0.9%	10
2013 Q4	$343M	Buy	5,140,000 +2,026,960	+65%	+$131M	0.82%	9
2013 Q3	$195M	Buy	3,113,040 +2,027,040	+187%	+$130M	0.47%	28
2013 Q2	$67.8M	Buy	+1,086,000	New	+$68.9M	0.18%	114

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies's GSK Position: Q1 2026 in Review

Renaissance Technologies reduced its GSK (GSK) stake by 70% in Q1 2026, selling an estimated $39.2M and leaving 311,292 shares worth $17.2M. The position accounts for 0.03% of the portfolio, ranked #718.

Renaissance Technologies first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $894M in Q4 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Renaissance Technologies held 311,292 shares of GSK worth $17.2M as of Q1 2026.
Renaissance Technologies sold 724,280 GSK shares in Q1 2026, an estimated $39.2M.
GSK made up 0.03% of Renaissance Technologies's portfolio in Q1 2026, its #718 holding.
Renaissance Technologies first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Renaissance Technologies's GSK position peaked at $894M in Q4 2019.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.